Efficacy, safety and tolerability of rasagiline as an add-on therapy to dopamine agonists in early Parkinson's disease: The ANDANTE study

Abstract

Background: Dopamine agonists (DAs) are often used as initial PD monotherapy. However with disease progression DA monotherapy alone becomes sub-optimal and patients often require additional dopaminergic therapy to maintain symptomatic efficacy. Traditional options at this stage include levodopa (associated with risk of dyskinesia) or increasing DA dose (associated with higher risks for ICDs and other AEs). Rasagiline is a selective, irreversible MAO-B inhibitor providing a distinct rationale as add-on therapy to DAs for additional symptomatic benefit.